George Priya Doss C, Rajith B, Chakraboty Chiranjib, Balaji V, Magesh R, Gowthami B, Menon Sneha, Swati M, Trivedi Manjari, Paul Jasmine, Vasan Richa, Das Maitreya
Medical Biotechnology Division, School of Biosciences and Technology, VIT University, Vellore 632014, Tamil Nadu, India.
Mol Biosyst. 2014 Mar 4;10(3):421-36. doi: 10.1039/c3mb70427k. Epub 2013 Dec 12.
A major challenge remaining in drug design efforts towards protein kinase is due to the development of drug resistance initiated by the missense mutations in the kinase catalytic domain. Gain or loss of function mutations in the REarranged during Transfection (RET) tyrosine kinase gene have been associated with the development of a wide range of human associated cancers and Hirschsprung's disease. However, to what extent these mutations might affect bio-molecular functions remains unclear. In this article, the functionally significant mutations in RET were screened with the aid of various sequence and structure based in silico prediction methods. We mapped the deleterious mutants, modelled mutant proteins and deciphered the impact of mutations on drug binding mechanisms in the RET crystal structure of PDB ID: with the potential inhibitor vandetanib by docking analysis. Furthermore, molecular dynamics simulations were undertaken to understand the mechanistic action of cancer associated mutations in altering the protein kinase structure, dynamics, and stability. According to our results, the overall effect of V804M, M918T and S922Y were destabilizing and mostly alter the electrostatic component of the binding energy. Specifically, the mutation of gatekeeper residue valine 804 present in the ATP binding pocket affects the protein stability and confers resistance to the drug vandetanib, which was consistent with previously published experimental results. Overall, our findings may provide useful structural insights for in-depth understanding of the molecular mechanism underlying RET mutation and developing effective drugs.
在针对蛋白激酶的药物设计工作中,仍然存在的一个主要挑战是激酶催化域中的错义突变引发的耐药性发展。转染重排(RET)酪氨酸激酶基因功能的获得或丧失突变与多种人类相关癌症和先天性巨结肠病的发生有关。然而,这些突变在多大程度上可能影响生物分子功能仍不清楚。在本文中,借助各种基于序列和结构的计算机预测方法,筛选了RET中具有功能意义的突变。我们绘制了有害突变体,对突变体蛋白进行建模,并通过对接分析在PDB ID的RET晶体结构中解读了突变对药物结合机制的影响:与潜在抑制剂凡德他尼结合。此外,进行了分子动力学模拟,以了解癌症相关突变在改变蛋白激酶结构、动力学和稳定性方面的作用机制。根据我们的结果,V804M、M918T和S922Y的总体影响是使蛋白不稳定,并且大多改变了结合能的静电成分。具体而言,ATP结合口袋中存在的守门残基缬氨酸804的突变影响蛋白稳定性,并赋予对药物凡德他尼的抗性,这与先前发表的实验结果一致。总体而言,我们的研究结果可能为深入理解RET突变背后的分子机制和开发有效药物提供有用的结构见解。